NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Status: Open to Accrual
Read More

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Status: Open to Accrual
Read More

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Status: Open to Accrual
Read More

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Status: Open to Accrual
Read More

Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder

Status: Open to Accrual 

Learn more: 

• https://clinicaltrials.gov/study/NCT06809140

Study contact: studies@hoosiercancer.org; (317) 921-2050.